Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Pembrolizumab versus ipilimumab for advanced melanoma - final overall survival results of a multicentre, randomised, open-label phase 3 study